BIOMAT Database Logo BIOMAT Database Logo

Osteoporosis in severe congenital neutropenia treated with granulocyte colony-stimulating factor. 1995

N J Bishop, and D M Williams, and J C Compston, and D M Stirling, and A Prentice
Department of Paediatrics, Addenbrooke's Hospital, Cambridge.

Recombinant human granulocyte colony-stimulating factor (G-CSF) has substantially improved life expectancy for children with severe congenital neutropenia (SCN). Severe osteoporosis, reported in this population, may relate to the disease process, or be a therapeutic side-effect. This report details bone loss, quantitated absorptiometrically and histomorphometrically, in a child with SCN and vertebral collapse, and the positive response to anabolic steroid and bisphosphonate therapy.

UI MeSH Term Description Entries
D009503 Neutropenia A decrease in the number of NEUTROPHILS found in the blood. Neutropenias
D010024 Osteoporosis Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis. Age-Related Osteoporosis,Bone Loss, Age-Related,Osteoporosis, Age-Related,Osteoporosis, Post-Traumatic,Osteoporosis, Senile,Senile Osteoporosis,Osteoporosis, Involutional,Age Related Osteoporosis,Age-Related Bone Loss,Age-Related Bone Losses,Age-Related Osteoporoses,Bone Loss, Age Related,Bone Losses, Age-Related,Osteoporoses,Osteoporoses, Age-Related,Osteoporoses, Senile,Osteoporosis, Age Related,Osteoporosis, Post Traumatic,Post-Traumatic Osteoporoses,Post-Traumatic Osteoporosis,Senile Osteoporoses
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004164 Diphosphonates Organic compounds which contain P-C-P bonds, where P stands for phosphonates or phosphonic acids. These compounds affect calcium metabolism. They inhibit ectopic calcification and slow down bone resorption and bone turnover. Technetium complexes of diphosphonates have been used successfully as bone scanning agents. Bisphosphonate,Bisphosphonates
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D016179 Granulocyte Colony-Stimulating Factor A glycoprotein of MW 25 kDa containing internal disulfide bonds. It induces the survival, proliferation, and differentiation of neutrophilic granulocyte precursor cells and functionally activates mature blood neutrophils. Among the family of colony-stimulating factors, G-CSF is the most potent inducer of terminal differentiation to granulocytes and macrophages of leukemic myeloid cell lines. Colony-Stimulating Factor, Granulocyte,G-CSF,Myeloid Growth Factor,Colony Stimulating Factor, Granulocyte,Factor, Granulocyte Colony-Stimulating,Factor, Myeloid Growth,Granulocyte Colony Stimulating Factor,Growth Factor, Myeloid
D045930 Anabolic Agents These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power. Anabolic Effect,Anabolic Effects,Agents, Anabolic,Effect, Anabolic,Effects, Anabolic

Related Publications

N J Bishop, and D M Williams, and J C Compston, and D M Stirling, and A Prentice
[Chronic congenital neutropenia treated with granulocyte colony-stimulating factor (G-CSF)].
February 1992, Ugeskrift for laeger,
N J Bishop, and D M Williams, and J C Compston, and D M Stirling, and A Prentice
Differential effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia.
March 1990, Blood,
N J Bishop, and D M Williams, and J C Compston, and D M Stirling, and A Prentice
Outcomes for patients with severe chronic neutropenia treated with granulocyte colony-stimulating factor.
July 2022, Blood advances,
N J Bishop, and D M Williams, and J C Compston, and D M Stirling, and A Prentice
Increased serum levels of granulocyte colony-stimulating factor in patients with severe congenital neutropenia.
May 1991, Blood,
N J Bishop, and D M Williams, and J C Compston, and D M Stirling, and A Prentice
Complication of rapidly progressive glomerulonephritis in severe congenital neutropenia treated with long-term granulocyte colony-stimulating factor (filgrastim).
July 2000, British journal of haematology,
N J Bishop, and D M Williams, and J C Compston, and D M Stirling, and A Prentice
Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia.
January 1997, Leukemia,
N J Bishop, and D M Williams, and J C Compston, and D M Stirling, and A Prentice
Effects of granulocyte colony-stimulating factor in children with severe neutropenia.
January 1994, Acta haematologica Polonica,
N J Bishop, and D M Williams, and J C Compston, and D M Stirling, and A Prentice
Severe osteopenia in a young boy with Kostmann's congenital neutropenia treated with granulocyte colony-stimulating factor: suggested therapeutic approach.
September 2001, Pediatrics,
N J Bishop, and D M Williams, and J C Compston, and D M Stirling, and A Prentice
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia.
June 1997, The New England journal of medicine,
N J Bishop, and D M Williams, and J C Compston, and D M Stirling, and A Prentice
[Long-term treatment with recombinant human granulocyte colony stimulating factor in patients with severe congenital neutropenia].
January 1993, Klinische Padiatrie,
Copied contents to your clipboard!